EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.

Autor:	Pinto, Icaro Alves, Cavagna, Rodrigo de Oliveira, Silva, Aline Larissa Virginio da, Dias, Josiane Mourão, Santana, Iara Vidigal, Souza, Laísa Caroline, Silva, Flávio Augusto Ferreira da, Fernandes, Maria Fernanda Biazotto, Pinto, Gustavo Dix Junqueira, Negreiros, Izabella Santos, Gonçalves, Maria Fernanda Santiago, Paula, Flávia Escremim de, Berardinelli, Gustavo Nóriz, Casagrande, Giovanna Maria Stanfoca, Silva, Marcela Oliveira da, Silva, Eduardo Caetano Albino da, Oliveira, Marco Antonio de, Jacinto, Alexandre Arthur, Silva, Vinicius Duval da, Reis, Rui Manuel
Předmět:	LUNG cancer & genetics LUNG cancer prognosis LUNG cancer GENETIC mutation SEQUENCE analysis EPIDERMAL growth factor ONCOGENES IMMUNOHISTOCHEMISTRY RETROSPECTIVE studies ACQUISITION of data FISHER exact test SEX distribution TUMOR classification MEDICAL records CHI-squared test SURVIVAL analysis (Biometry) KAPLAN-Meier estimator WEIGHT loss SOCIODEMOGRAPHIC factors LOGISTIC regression analysis PROGRESSION-free survival SMOKING PROPORTIONAL hazards models
Zdroj:	Oncologist; Nov2022, Vol. 27 Issue 11, pe899-e907, 9p, 3 Charts, 2 Graphs
Abstrakt:	Background Targeted and immunotherapies are currently moving toward early-stage settings for patients with non-small cell lung cancer (NSCLC). Predictive biomarkers data are scarce in this scenario. We aimed to describe the frequency of EGFR mutations and PD-L1 expression levels in early-stage non-squamous patients with NSCLC from a large, single Brazilian oncology center. Methods We retrospectively evaluated patients with NSCLC diagnosed at an early-stage (IB to IIIA-AJCC seventh edition) at Barretos Cancer Hospital (n = 302). EGFR mutational status was assessed in FFPE tumor tissues using distinct methodologies (NGS, Cobas, or Sanger sequencing). PD-L1 expression was evaluated by immunohistochemistry (clone 22C3) and reported as Tumor Proportion Score (TPS), categorized as <1%, 1-49%, and ≥50%. We evaluated the association between EGFR mutational status and PD-L1 expression with sociodemographic and clinicopathological parameters by Fisher's test, qui-square test, and logistic regression. Survival analysis was assessed by the Kaplan-Meier method and Cox regression model. Results EGFR mutations were detected in 17.3% (n = 48) of cases and were associated with female sex, never smokers, and longer overall and event-free survival. PD-L1 positivity was observed in 36.7% (n = 69) of cases [TPS 1-49% n = 44(23.4%); TPS ≥50% n = 25(13.3%)]. PD-L1 positivity was associated with smoking, weight loss, and higher disease stages (IIB/IIIA). Conclusion The frequencies of EGFR mutations and PD-L1 positivity were described for early-stage non-squamous patients with NSCLC. These results will be essential for guiding treatment strategies with the recent approvals of osimertinib and immunotherapy in the adjuvant setting. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu